Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide
Access to this document is restricted. Some items have been embargoed at the request of the author, but will be made publicly available after the "No Access Until" date.
During the embargo period, you may request access to the item by clicking the link to the restricted file(s) and completing the request form. If we have contact information for a Cornell author, we will contact the author and request permission to provide access. If we do not have contact information for a Cornell author, or the author denies or does not respond to our inquiry, we will not be able to provide access. For more information, review our policies for restricted content.
Objective: This study compared weight-loss outcomes in patients prescribed tirzepatide by weight-loss status and assessed results among patients transitioning from semaglutide. Methods: This retrospective cohort study analyzed 6-month weight-loss outcomes in adults treated with tirzepatide between May 2022 and January 2023. Patients were classified as weight-reduced if they had lost ≥ 10% total body weight (TBW) before starting tirzepatide. Among those who switched from therapeutic semaglutide (≥ 1.7 mg weekly for ≥ 1 month), reasons for switching were categorized as non-response (< 5% weight loss after ≥ 3 months), plateau (≥ 5% loss followed by weight stabilization), or other. Results: Of 941 charts, 293 (31.1%) met inclusion criteria (65% female; mean age 52 years; mean BMI 36.15 kg/m2). Weight-reduced patients (n = 133) lost 7.2% TBW versus 10.3% in non-weight-reduced patients (n = 160; p < 0.001). When analyses were stratified by type 2 diabetes (T2D) status, this difference remained significant among patients without T2D. Sixty-one patients switched from semaglutide due to non-response or plateau and lost 5.3% TBW. Those switching at a plateau (n = 28) lost 8.1% versus 2.9% for non-responders (n = 33; p < 0.001). Conclusions: Tirzepatide produced meaningful weight loss across groups but outcomes varied based on weight-reduction status, T2D status, and prior response to semaglutide.